EFFICACY RESULTS FROM THE RANDOMISED PHASE III OPTIMAL (CTONG 0802) STUDY COMPARING FIRST-LINE ERLOTINIB VERSUS CARBOPLATIN (CBDCA) PLUS GEMCITABINE (GEM), IN CHINESE ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) PATIENTS (PTS) WITH EGFR ACTIVATING MUTATIONS

IR@PKUHSC > 北京大学临床肿瘤学院

学科主题	临床医学
	EFFICACY RESULTS FROM THE RANDOMISED PHASE III OPTIMAL (CTONG 0802) STUDY COMPARING FIRST-LINE ERLOTINIB VERSUS CARBOPLATIN (CBDCA) PLUS GEMCITABINE (GEM), IN CHINESE ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) PATIENTS (PTS) WITH EGFR ACTIVATING MUTATIONS
	Zhou, C.1; Wu, Y-L.2,3; Chen, G.4; Feng, J.5; Liu, X.6; Wang, C.7; Zhang, S.8; Wang, J.9; Zhou, S.1; Ren, S.1; OPTIMAL Investigators
刊名	ANNALS OF ONCOLOGY
	2010-10-01
卷	suppl.8 页:6-6
收录类别	SCI ; ISTP
文章类型	Meeting Abstract
WOS标题词	Science & Technology
类目[WOS]	Oncology
研究领域[WOS]	Oncology
语种	英语
WOS记录号	WOS:000283115900014
引用统计	被引频次：36[WOS] [WOS记录] [WOS相关记录]
文献类型	期刊论文
条目标识符	http://ir.bjmu.edu.cn/handle/400002259/55553
专题	北京大学临床肿瘤学院
作者单位	1.Beijing Chest Hosp, Beijing, Peoples R China 2.Tongji Univ, Shanghai Pulm Hosp, Shanghai 200092, Peoples R China 3.Guangdong Gen Hosp, Guangdong Lung Canc Inst, Guangzhou, Guangdong, Peoples R China 4.Harbin Med Coll, Canc Hosp, Harbin, Peoples R China 5.Jiangsu Prov Canc Hosp, Nanjing, Peoples R China 6.Tianjin Canc Hosp, Tianjin, Peoples R China 7.Guangdong Acad Med Sci, Guangzhou, Guangdong, Peoples R China 8.Acad Mil Med Sci, Hosp 307, Ctr Canc, Beijing, Peoples R China 9.Peking Univ, Sch Oncol, Beijing Canc Hosp, Beijing 100871, Peoples R China
推荐引用方式 GB/T 7714	Zhou, C.,Wu, Y-L.,Chen, G.,et al. EFFICACY RESULTS FROM THE RANDOMISED PHASE III OPTIMAL (CTONG 0802) STUDY COMPARING FIRST-LINE ERLOTINIB VERSUS CARBOPLATIN (CBDCA) PLUS GEMCITABINE (GEM), IN CHINESE ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) PATIENTS (PTS) WITH EGFR ACTIVATING MUTATIONS[J]. ANNALS OF ONCOLOGY,2010,suppl.8:6-6.
APA	Zhou, C..,Wu, Y-L..,Chen, G..,Feng, J..,Liu, X..,...&OPTIMAL Investigators.(2010).EFFICACY RESULTS FROM THE RANDOMISED PHASE III OPTIMAL (CTONG 0802) STUDY COMPARING FIRST-LINE ERLOTINIB VERSUS CARBOPLATIN (CBDCA) PLUS GEMCITABINE (GEM), IN CHINESE ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) PATIENTS (PTS) WITH EGFR ACTIVATING MUTATIONS.ANNALS OF ONCOLOGY,suppl.8,6-6.
MLA	Zhou, C.,et al."EFFICACY RESULTS FROM THE RANDOMISED PHASE III OPTIMAL (CTONG 0802) STUDY COMPARING FIRST-LINE ERLOTINIB VERSUS CARBOPLATIN (CBDCA) PLUS GEMCITABINE (GEM), IN CHINESE ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC) PATIENTS (PTS) WITH EGFR ACTIVATING MUTATIONS".ANNALS OF ONCOLOGY suppl.8(2010):6-6.